

Older adults (OA) age 70+ experience similar survival outcomes to younger adults (YA) age <70 receiving 2nd line therapy for metastatic CRC (mCRC): analysis of 5289 patients (pts) from the ARCAD Clinical Trials Program

Authors: NJ McCleary MD MPH, WS Harmsen MS, E VanCutsem MD, AF Sobrero MD, RM Goldberg MD, FASCO, J Taberero MD, M Seymour MD, LB Saltz MD, BJ Giantonio MD, A Dirk MD, ML Rothenberg MD, M Koopman MD, HJ Schmolli MD, HC Pitot MD, PM Hoff MD, NC Tebbutt MD, A Falcone MD, A deGramont MD, Q Shi PhD, SM Lichtman MD



Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Leuven, Leuven, Belgium; IRCCS Ospedale San Martino IST, Genova, Italy; West Virginia University Cancer Institute, Morgantown, WV; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; NIHR Clinical Research Network, Leeds UK St James's Hospital, and University of Leeds, Leeds, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; University of Pennsylvania Abramson Cancer Center, Philadelphia, MA; Instituto CUF de Oncologia, Lisbon, Portugal; Pfizer Inc., New York, NY; University Medical Center Utrecht, Utrecht, Netherlands; Martin Luther University, Halle, Germany; Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil; Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Franco-British Institute, Levallois-Perret, France

BACKGROUND

Survival outcomes of first line therapy for older adults diagnosed with mCRC has been established in clinical trial and SEER-Medicare studies but survival outcomes of 2nd line mCRC therapy for older adults are poorly understood.

OBJECTIVES

To evaluate the rates and survival outcomes of 2nd line therapy among older adults age 70+ compared to younger adults age <70 following progression on 1st line clinical trials.

METHODS

Analysis was done on 10 first line trials with available subsequent treatment data for patients after progression. The associations between patient/disease/clinical characteristics, time to initial progression and rate of receipt of 2nd line therapy were analyzed. Time to progression and overall survival between older and younger adults were evaluated with Cox regression, adjusting for key clinical and disease characteristics (age, gender, ECOG PS, number of metastatic sites, presence of metastasis in lung/liver/peritoneum).

RESULTS

Characteristic		1st line therapy TTiP N= 5289 (5121 evaluable)				2nd line therapy TTP N=7921 (7408 evaluable)		2nd line therapy OS N=8280 (7764 evaluable)	
			OR (95% CI)	P-value		HR (95% CI)	P-value	HR (95% CI)	P-value
Enrollment age – mean (SD)		59.8 (10.7)	1.11 (1.02, 1.21)	0.012	Age, per 10 yrs	0.97 (0.94,0.99)	0.005	0.99 (0.97,1.02)	0.618
Sex – no. (%)	Male	2880 (87.2)	1.15 (0.96,1.38) (Female Referent)	0.121		0.98 (0.94,1.04)	0.54	0.97 (0.92,1.02)	0.204
ECOG PS – no. (%)	0	2566 (90.4)	Referent						
	1	1815 (85.8)	1.55 (1.30,1.84)			1.22 (1.16,1.28)		1.51 (1.43, 1.59)	
	>1	115(69.7)	4.07 (2.85, 5.82)	<0.0001		1.59 (1.38,1.83)	<0.001	3.54 (3.13,4.02)	<0.0001
Metastasis	Lung	1562 (87.4)	1.03 (0.86,1.23)	0.761		1.10 (1.04,1.18)	0.003	1.08 (1.01,1.16)	0.02
	Liver	3421 (88.0)	0.90 (0.75, 1.09)	0.291		1.36 (1.28,1.45)	<0.001	1.62 (1.52,1.74)	<0.001
	Peritoneum	407 (88.1)	0.92 (0.68, 1.24)	0.571		1.27 (1.03,1.57)	0.025	1.42 (1.14,1.75)	0.001

FIGURE 1 – mTTP for second line participants by age ≤70 and >70





FIGURE 2 – mOS for second line participants by age ≤70 and >70



KEY FINDINGS

- Older adults (age 70+) and ECOG PS > 0 were less likely to receive second line therapy than adults age <70
- Odds of receiving second line therapy decreased by 11% for each additional decade of life in multivariate analysis (p = 0.0117)
- Older adults enrolled in second line trials experience similar mTTP (5.1 vs. 5.2mos) and mOS (11.6 vs. 12.4mos) as younger adults.

CONCLUSIONS

- Fewer older adults participate in second line randomized clinical trials for mCRC.
- In second line CRC trials, survival outcomes for older adults are similar to those of younger adults.

ACKNOWLEDGMENTS

Supported by La Fondation A.R.C.A.D., Aide et Recherche en CAncérologie Digestive and Dana-Farber/Harvard Cancer Center Gastrointestinal SPORE NCI 5P50CA127003-08